Summit Therapeutics Inc.
Company Stats
- Market Cap
- $13.5B
- as of Sep 30, 2026
- Shares Outstanding
- 797.7M
- Free Float
- 21.4%
Income Statement
- Net Income
- -$1.1B
Cash Flow
- Free Cash Flow
- -$323.6M
- FCF Yield
- -2.4%
- Owner FCF Yield
- -7.8%
Balance Sheet
- Cash & Equivalents
- $225.3M
Returns & Capital
- SBC, 3Y Avg
- $265.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$323.6M | — |
| FY2024 | $0 | -$142.2M | — |
| FY2023 | $0 | -$76.9M | — |
| FY2022 | $705,000 | -$42.2M | -5986.7% |
| FY2021 | $1.8M | -$72.9M | -4029.5% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
AstraZeneca to Invest $2 Billion in Summit Therapeutics
Stronger demand supports expansion as pricing diverges
Concentrated Conviction in Specialty Finance and Biotech